Anthony Sung

Professional Background

Anthony Sung, MD, is the A. Drue Jennings Professor in Medical Oncology, Professor of Medicine in Division of Hematologic Malignancies and Cellular Therapy, and Director of the Center for Survivorship and Patient-Oriented Research, University of Kansas Medical Center. California born and bred, he received his undergraduate degree from Stanford University, though he spent his junior year "abroad" at Deep Springs College. He subsequently received his MD from Harvard Medical School, did his internship and residency in internal medicine at Johns Hopkins Hospital in the Osler Medical Housestaff Training Program, and fellowship in hematology/oncology at Duke University. Upon completion of his training, he spent 10 years on the faculty at Duke, where he served as Associate Director of the Duke Microbiome Center and a Senior Fellow in the Duke Center for the Study of Aging and Human Development before coming to KUMC in 2024. In addition to his work at KUMC, Dr. Sung is a Special Government Employee of the United States Food and Drug Administration (FDA) and ad hoc member of the FDA Oncologic Drug Advisory Committee (ODAC); a member of the American Society of Hematology (ASH) Subcommittee on Emerging Gene and Cellular Therapies, and a member of the Bone Marrow Transplant Clinical Trials Network (BMT CTN) Toxicity and Supportive Care Committee.

• BS, Science, Technology, and Society, Stanford University
• MD, Medicine, Harvard Medical School
• MS, Clinical Research, Duke University
• Residency, Internal Medicine, Johns Hopkins Hospital
• Clinical Fellowship, Hematology/Oncology, Duke University

Research

Overview

As a hematopoietic stem cell transplant physician, Dr. Sung's clinical/translational research program focuses on reducing transplant-related complications and improving survivorship through bedside-to-bench and bench-to-bedside studies and phase 1/2 clinical trials. Areas of investigation include survivorship, function, and quality of life; exercise and behavioral interventions; mobile health and remote monitoring; care delivery at home; accelerated aging after cancer treatment; and prebiotics and the microbiome. His work has been funded by the National Cancer Institute (NCI), National Heart Lung and Blood Institute (NHLBI), National Institute on Aging (NIA), National Institute for Allergy and Infectious Diseases (NIAID), and National Institute of Child Health and Human Development (NICHD); several philanthropic foundations including the American Society of Hematology (ASH), Leukemia and Lymphoma Society (LLS), Damon Runyon Cancer Research Foundation, and several industry partners.

• R01AG066719 Home-based Autologous Hematopoietic Stem Cell Transplantation to Improve Outcomes and Decrease Costs, NIA, PI
• R01HL151365 Prebiotics to Optimize the Microbiota and Improve Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation, NHLBI, PI
• R01NR021468 Addressing Food Insecurity in Transplant and Cellular Therapy Patients with Healthcare-Community Partnerships, NINR, PI
• R01CA244172 Using a SMART Design to Optimize PTSD Symptom Management Strategies Among Cancer Survivors, NCI, Co-I
• R01HD107103 Remotely Monitored, Mobile health-supported High Intensity Interval Training after COVID-19 Critical Illness (REMM HIIT-Covid19), NICHD, Co-I